iShares Morningstar Mid-Cap Growth ETFIMCG

On 26 July 2026, the iShares Morningstar Mid-Cap Growth ETF (IMCG) remains a textbook example of how an ETF wrapper can turn a simple index-tracking mandate into a slick marketing exercise. The fund’s stated goal is to provide exposure to US mid-cap growth companies, but the reality is a static basket of stocks selected by Morningstar’s methodology and managed by BlackRock’s machinery. The issuer’s official ETF centre pages are polished, full of aspirational imagery, and light on granular detail about the fund’s actual holdings or performance. The fund’s expense ratio of 0.06% is marketed as a bargain, but it’s a fee extracted from investors who bought into the pitch, not the substance.

The fund’s top holdings-including DexCom, Advanced Micro Devices, and Copart-are mid-cap growth names that should be familiar to anyone who’s ever glanced at a mid-cap growth index. These are not obscure moonshots; they’re the kind of stocks that populate dozens of similar funds. The issuer’s UK site even admits that most UK regulatory protections do not apply to this product, a disclosure that reads like a disclaimer for a financial bungee jump. The fund’s AUM and liquidity are healthy, but the fees are quietly siphoning value from investors who believed the marketing.

The fund’s mandate is to track the Morningstar US Mid Cap Growth Index, a methodology that selects stocks based on growth characteristics like earnings growth and sales growth. The index is rules-based, so the fund’s performance is entirely dependent on the index’s composition and Morningstar’s methodology. There’s no active management here, just a fee taken from investors for the privilege of owning a basket of mid-cap growth stocks. The issuer’s product pages promise "expert management" and "innovation," but the fund’s holdings are, at best, a curated slice of the mid-cap growth universe. The fee is the only thing that’s actively managed, and it’s a quiet, relentless nibble at returns.

For context, the fund is listed on Nasdaq under the ticker IMCG, where you can track its daily price movements and trading volumes. The SEC’s EDGAR database confirms the fund’s registration and filing history, but there’s no evidence here of earnings surprises, revenue beats, or guidance updates-because there are none to report. The fund’s performance is tied to the index, and the index’s performance is tied to the fortunes of mid-cap growth stocks. If those stocks stumble, the fund stumbles with them. The chart route for IMCG on Nasdaq is available for those who wish to track its price action, but remember: the chart reflects the fee as much as the stocks.

What’s missing from the evidence is any indication that the fund’s holdings or performance have deviated from the index’s expectations. There’s no sign of a rebalancing surprise, no earnings catalyst, and no regulatory filing that suggests the fund’s methodology is under review. The issuer’s marketing materials promise "AI-related products" and "capture AI’s potential growth," but IMCG’s holdings are not dominated by AI stocks. The fund’s top holdings are mid-cap growth names, not pure-play AI companies. The disconnect between the marketing and the reality is the real story here. To deepen this file, we’d need evidence of a shift in the fund’s holdings, a change in the index methodology, or a regulatory filing that suggests the fund’s operations are under scrutiny.